Corcept Therapeutics (NASDAQ:CORT) Downgraded by Zacks Research to “Hold”

Posted by George Bondi on Oct 29th, 2026

Zacks Research lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a hold rating in a report published on Tuesday,Zacks reports.

Other research analysts also recently issued reports about the stock. Truist Financial initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, August 18th. They set a “buy” rating and a $164.00 price target on the stock. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Piper Sandler reaffirmed an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Weiss Ratings raised shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, September 24th. Finally, Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a research note on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $138.17.

Check Out Our Latest Analysis on CORT

Corcept Therapeutics Stock Down 1.5%

Shares of CORT stock opened at $86.28 on Tuesday. The company has a 50 day moving average of $113.44 and a 200-day moving average of $74.16. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $126.38. The firm has a market cap of $9.33 billion, a P/E ratio of 205.43 and a beta of 0.40.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%. The business had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter in the prior year, the firm posted $0.29 EPS. The firm’s quarterly revenue was up 31.7% on a year-over-year basis. As a group, equities analysts expect that Corcept Therapeutics will post 1.83 EPS for the current year.

Insider Transactions at Corcept Therapeutics

In related news, Director James N. Wilson sold 10,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $114.81, for a total value of $1,148,100.00. Following the completion of the transaction, the director owned 1,054,543 shares in the company, valued at approximately $121,072,081.83. This trade represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Joseph Lyon sold 9,190 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $116.13, for a total value of $1,067,234.70. Following the sale, the insider owned 5,683 shares in the company, valued at $659,966.79. The trade was a 61.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 374,748 shares of company stock valued at $43,609,410. 20.70% of the stock is owned by company insiders.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently modified their holdings of CORT. Profund Advisors LLC lifted its position in Corcept Therapeutics by 130.8% during the 3rd quarter. Profund Advisors LLC now owns 15,351 shares of the biotechnology company’s stock worth $1,769,000 after acquiring an additional 8,700 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Corcept Therapeutics during the 3rd quarter worth about $417,000. Vise Technologies Inc. grew its position in shares of Corcept Therapeutics by 91.1% during the 3rd quarter. Vise Technologies Inc. now owns 17,901 shares of the biotechnology company’s stock valued at $2,063,000 after acquiring an additional 8,535 shares during the period. Summit Global Investments purchased a new position in shares of Corcept Therapeutics in the 3rd quarter valued at about $1,382,000. Finally, State of Wyoming acquired a new position in Corcept Therapeutics in the 3rd quarter worth about $182,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.